Alternative lengthening of telomeres in hTERT-inhibited laryngeal cancer cells

Cancer Science

Volumn 101, Issue 8, 2010, Pages 1769-1776

  Chen, Wei ^a   Xiao, Bo Kui ^a   Liu, Jun Ping ^b   Chen, Shi Ming ^a   Tao, Ze Zhang ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; GREEN FLUORESCENT PROTEIN; GROWTH ARREST SPECIFIC PROTEIN 8; SHORT HAIRPIN RNA; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ALTERNATIVE LENGTHENING OF TELOMERE; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CELL SELECTION; CELL SURVIVAL; CELL VIABILITY; CHROMOSOME SIZE; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC TRANSFECTION; HEP 2 CELL; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LARYNX CANCER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RNA INTERFERENCE; SISTER CHROMATID EXCHANGE; TELOMERE; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LARYNGEAL NEOPLASMS; MICE; NEOPLASM INVASIVENESS; PROTEOMICS; RNA INTERFERENCE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TELOMERASE; TELOMERE;

EID: 77954858289     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01611.x     Document Type: Article

References (27)

1. Opitz OG. Telomeres, telomerase and malignant transformation. Curr Mol Med 2005, 5:219-26.
2. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. Science 2007, 315:1850-3.
3. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995, 14:4240-8.
4. Bollmann FM. Targeting ALT: the role of alternative lengthening of telomeres in pathogenesis and prevention of cancer. Cancer Treat Rev 2007, 33:704-9.
5. Bailey SM, Brenneman MA, Goodwin EH. Frequent recombination in telomeric DNA may extend the proliferative life of telomerase-negative cells. Nucleic Acids Res 2004, 32:3743-51.
6. Nittis T, Guittat L, Stewart SA. Alternative lengthening of telomeres (ALT) and chromatin: is there a connection? Biochimie 2008, 90:5-12.
7. Venturini L, Erdas R, Costa A. ALT-associated promyelocytic leukaemia body (APB) detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcomas. J Pathol 2008, 214:410-4.
8. Bechter OE, Zou Y, Walker W, Wright WE, Shay JW. Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition. Cancer Res 2004, 64:3444-51.
9. Perrem K, Colgin LM, Neumann AA, Yeager TR, Reddel RR. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol 2001, 21:3862-75.
10. Kumakura S, Tsutsui TW, Yagisawa J, Barrett JC, Tsutsui T. Reversible conversion of immortal human cells from telomerase-positive to telomerase-negative cells. Cancer Res 2005, 65:2778-86.
11. Chen SM, Tao ZZ, Hua QQ. Inhibition of telomerase activity in cancer cells using short hairpin RNA expression vectors. Cancer Invest 2007, 25:691-8.
12. Chen SM, Tao ZZ, Hua QQ, Liu D, Chi HM, Cai Q. Inhibition of human telomerase reverse transcriptase in hep-2 cells using short hairpin RNA expression vectors. Arch Otolaryngol Head Neck Surg 2006, 132:200-5.
13. Fitzpatrick R, Davies L. Health economics and quality of life in cancer trials: report based on a UKCCCR workshop. United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1998, 77:1543-8.
14. Bailey SM, Goodwin EH, Meyne J, Cornforth MN. CO-FISH reveals inversions associated with isochromosome formation. Mutagenesis 1996, 11:139-44.
15. Londono-Vallejo JA, Der-Sarkissian H, Cazes L, Bacchetti S, Reddel RR. Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res 2004, 64:2324-7.
16. Benetti R, Garcia-Cao M, Blasco MA. Telomere length regulates the epigenetic status of mammalian telomeres and subtelomeres. Nat Genet 2007, 39:243-50.
17. Jiang WQ, Zhong ZH, Henson JD, Reddel RR. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene 2007, 26:4635-47.
18. Groff-Vindman C, Cesare AJ, Natarajan S, Griffith JD, McEachern MJ. Recombination at long mutant telomeres produces tiny single- and double-stranded telomeric circles. Mol Cell Biol 2005, 25:4406-12.
19. Reddel RR. Alternative lengthening of telomeres, telomerase, and cancer. Cancer Lett 2003, 194:155-62.
20. Varley H, Pickett HA, Foxon JL, Reddel RR, Royle NJ. Molecular characterization of inter-telomere and intra-telomere mutations in human ALT cells. Nat Genet 2002, 30:301-5.
21. Wu G, Jiang X, Lee WH, Chen PL. Assembly of functional ALT-associated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1. Cancer Res 2003, 63:2589-95.
22. Tarsounas M, Munoz P, Claas A. Telomere maintenance requires the RAD51D recombination/repair protein. Cell 2004, 117:337-47.
23. Grobelny JV, Godwin AK, Broccoli D. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. J Cell Sci 2000, 24:4577-85.
24. Zhu XD, Kuster B, Mann M, Petrini JH, de Lange T. Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. Nat Genet 2000, 25:347-52.
25. Wu G, Lee WH, Chen PL. NBS1 and TRF1 colocalize at promyelocytic leukemia bodies during late S/G2 phases in immortalized telomerase-negative cells. Implication of NBS1 in alternative lengthening of telomeres. J Biol Chem 2000, 275:30618-22.
26. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999, 59:4175-9.
27. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2006, 94:179-83.